**Additional File1**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Interventions** | **NCT number** | **Title** | **Indications** | **Characteristics** | **Recruiting** |
| Metformin | NCT02115464 | Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy (ALMERA) | NSCLC | Phase 2 | Terminated |
| Metformin | NCT02285855 | Metformin in non-small cell lung cancer (NSCLC) | NSCLC | Phase 2 | Published |
| Metformin | NCT04931017 | Metformin for chemoprevention of lung cancer in obese individuals at high risk for lung Cancer | NSCLC | Phase 2 | Not yet recruiting |
| Metformin | NCT02019979 | Metformin and carbohydrate restriction with platinum based chemotherapy in stage iiib/iv non-squamous non-small cell lung cancer (NS-NSCLC) | NSCLC | Phase 2 | Published |
| Metformin | NCT03086733 | Phase II Lung Metcore - Preoperative metformin for lung cancer | NSCLC | Phase 2 | Completed |
| Metformin | NCT01717482 | Metformin as a chemoprevention agent in non-small cell lung cancer | NSCLC | Phase 2 | Published |
| Metformin | NCT01997775 | Metformin in Stage IV LUAD | NSCLC | Phase 2 | Terminated |
| Metformin | NCT02109549 | Influence of the use of the diabetic drug metformin on the OS and treatment-related toxicity in advanced stage non-small cell lung cancer patients. | NSCLC | Phase 2 | Completed |
| Metformin | NCT03874000 | Sintilimab combined with metformin in first-line chemotherapy refractory advanced NSCLC Patients | NSCLC | Phase 2 | Recruiting |
| Metformin | NCT03048500 | Nivolumab and metformin hydrochloride in treating patients with stage III-IV non-small cell lung cancer that cannot be removed by surgery | NSCLC | Phase 2 | Published |
| Metformin | NCT03994744 | assessing safety and efficacy of sintilimab and metformin combination therapy in SCLC | SCLC | Phase 2 | Recruiting |
| Metformin | NCT04001725 | Efficacy of metformin in preventing glucocorticoid-induced diabetes in patients with brain metastases | NSCLC, Melanoma, Breast cancer | Phase 2 | Recruiting |
| Metformin | NCT03071705 | Metformin plus TKI Use in patients with non-small cell lung carcinoma | NSCLC, EGFR+ | Phase 2 | Published |
| Metformin | NCT02186847 | Chemotherapy and radiation therapy with or without metformin hydrochloride in treating patients with stage iii non-small cell lung cancer | NSCLC | Phase 2 | Published |
| Metformin | NCT04170959 | The addition of metformin to definitive radiotherapy in patients with stage III NSCLC | NSCLC | Phase 2 | Terminated |
| Metformin | NCT01864681 | Combination of metformin with gefitinib to treat NSCLC | NSCLC | Phase 2 | Completed |
| Metformin | NCT00659568 | Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma | NSCLC,Breast cancer, kidney cancer, lymphoma | Phase 1 | Completed |
| Metformin | NCT02145559 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors | NSCLC,Breast cancer, liver cancer | Phase 1 | Completed |
| Metformin | NCT02431676 | Survivorship promotion In Reducing IGF-1 Trial | NSCLC, Breast cancer, prostate cancer | Phase 2 | Completed |
| Metformin | NCT01578551 | Study of metformin plus paclitaxel/carboplatin/bevacizumab in patients with adenocarcinoma. | LUAD | Phase 2 | Published |
| Metformin | NCT03709147 | Metformin plus/minus fasting mimicking diet to target the metabolic vulnerabilities of LKB1-inactive LUAD | LUAD | Phase 2 | Recruiting |
| ME344 | NCT02100007 | ME-344 Given in combination with hycamtin® in patients with solid tumors | Solid tumor including SCLC | Phase 2 | Published |